- Home
- GGAL vs MRUS Comparison
GGAL vs MRUS Comparison
Compare GGAL & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGAL
- MRUS
- Stock Information
- Founded
- GGAL 1905
- MRUS 2003
- Country
- GGAL Argentina
- MRUS Netherlands
- Employees
- GGAL N/A
- MRUS N/A
- Industry
- GGAL Commercial Banks
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- GGAL Finance
- MRUS Health Care
- Exchange
- GGAL Nasdaq
- MRUS Nasdaq
- Market Cap
- GGAL 5.1B
- MRUS 5.1B
- IPO Year
- GGAL N/A
- MRUS 2016
- Fundamental
- Price
- GGAL $28.18
- MRUS $94.38
- Analyst Decision
- GGAL Buy
- MRUS Buy
- Analyst Count
- GGAL 3
- MRUS 18
- Target Price
- GGAL $76.00
- MRUS $93.72
- AVG Volume (30 Days)
- GGAL 3.3M
- MRUS 4.2M
- Earning Date
- GGAL 01-01-0001
- MRUS 10-30-2025
- Dividend Yield
- GGAL 2.48%
- MRUS N/A
- EPS Growth
- GGAL N/A
- MRUS N/A
- EPS
- GGAL 0.60
- MRUS N/A
- Revenue
- GGAL $4,565,013,669.00
- MRUS $56,228,000.00
- Revenue This Year
- GGAL $9.54
- MRUS $47.25
- Revenue Next Year
- GGAL $12.92
- MRUS N/A
- P/E Ratio
- GGAL $5.26
- MRUS N/A
- Revenue Growth
- GGAL N/A
- MRUS 59.77
- 52 Week Low
- GGAL $25.89
- MRUS $33.19
- 52 Week High
- GGAL $74.00
- MRUS $94.56
- Technical
- Relative Strength Index (RSI)
- GGAL 37.10
- MRUS 86.42
- Support Level
- GGAL $26.06
- MRUS $66.13
- Resistance Level
- GGAL $29.01
- MRUS $94.39
- Average True Range (ATR)
- GGAL 1.83
- MRUS 1.11
- MACD
- GGAL 0.47
- MRUS 1.89
- Stochastic Oscillator
- GGAL 19.36
- MRUS 99.47
About GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.